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A B S T R A C T
Background: Radiomics analyses has been proposed to interrogate the biology of tumour as well as to predict/
assess response to therapy in vivo. The objective of this work was to assess the sensitivity of radiomics fea-
tures to noise, resolution, and tumour volume in the context of a co-clinical trial.
Methods: Triple negative breast cancer (TNBC) patients were recruited into an ongoing co-clinical imaging
trial. Sub-typed matched TNBC patient-derived tumour xenografts (PDX) were generated to investigate opti-
mal co-clinical MR radiomic features. The MR imaging protocol included T1-weighed and T2-weighted imag-
ing. To test the sensitivity of radiomics to resolution, PDX were imaged at three different resolutions.
Multiple sets of images with varying signal-to-noise ratio (SNR) were generated, and an image independent
patch-based method was implemented to measure the noise levels. Forty-eight radiomic features were
extracted from manually segmented 2D and 3D segmented tumours and normal tissues of T1- and T2-
weighted co-clinical MR images.
Findings: Sixteen radiomics features were identified as volume dependent and corrected for volume-depen-
dency following normalization. Features from grey-level run-length matrix (GLRLM), grey-level size zone
matrix (GLSZM) were identified as most sensitive to noise. Radiomic features Kurtosis and Run-length vari-
ance (RLV) from GLSZM were most sensitive to changes in resolution in both T1w and T2w MRI. In general,
3D radiomic features were more robust compared to 2D (single slice) measures, although the former exhib-
ited higher variability between subjects.
Interpretation: Tumour volume, noise characteristics, and image resolution significantly impact radiomic
analysis in co-clinical studies.











Co-clinical trials recently emerged as an area of investigation in
which a clinical trial is coupled with a corresponding preclinical trial
to inform the corresponding clinical trial [18]. The preclinical arm
of the co-clinical trial generally uses genetically engineered mouse
models (GEMMs) of human cancer or patient-derived tumour
xenografts (PDXs) to aid in assessing therapeutic efficacy, patient
stratification, and to design optimal treatment strategies [2,9]. The
emergence of GEMMs and PDXs as a co-clinical paradigm is largely
motivated by the realization that established cell-lines do not reca-
pitulate the heterogeneity of human tumours and the diversity of
tumour phenotypes [10] and that better oncology models are needed
to support high-impact translational cancer research. To that end, the
National Cancer Institute (NCI) and numerous European entities have
launched wide-ranging programs to support co-clinical trials (e.g.
Co-Clinical Imaging Research Resource Program, (https://nciphub.
org/groups/cirphub; EuroPDX, https://www.europdx.eu). The use of
PDX, in particular, offers numerous advantages in translational imag-
ing research; chief among them is retention of human tumour
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heterogeneity, which can be exploited to develop and validate image
metrics of heterogeneity and response to therapy. To that end, radio-
mics analyses of tumours, broadly defined as the process of extract-
ing image features from medical images, has been proposed to
interrogate tumour heterogeneity in vivo [1113].
Indeed, radiomic analyses pipelines are widely applied to predict
and assess response to therapy as well as aid in stratification of
patients in clinical trials [1420]. Importantly, as preclinical imaging
is a critical component in the translational drug discovery pipeline, a
bi-directional translation and implementation of quantitative imag-
ing methodologies is needed to support translational studies in
assessing the efficacy of novel therapeutics and their validation in the
clinical setting. However, numerous considerations are warranted in
designing co-clinical imaging studies with radiomic endpoints, in
particular if the objective is for preclinical imaging standards to meet
or exceed clinical imaging standards. Differences in scale (human vs.
mouse) yield smaller voxel sizes and reduced signal-to-noise (SNR)
in preclinical imaging. Since image features are a function of voxel
density, a measure of resolution-to-scale is needed to harmonize co-
clinical radiomic analysis. Finally, radiomic features may be depen-
dent on tumour volume, and ideally volume-independent features
should be used in extraction of tumour features as to not bias image
metrics longitudinally. These considerations have broad implications
in designing co-clinical trials with radiomic endpoints. In light of
these considerations, in this work we characterize the sensitivity of
radiomics features to noise, image resolution, and tumour volume in
context of a prospective co-clinical trial.
The sensitivity of forty-eight radiomics features, broadly catego-
rized as first order features, second order statistics, and higher-order
features, were extracted from tumour and muscle regions of pre-
treatment MR images (preclinical). Measures of image noise such
signal-to-noise (SNR) ratio and root mean square error (RMSE) were
determined. In addition, an algorithm was implemented to calibrate
noise characteristics between preclinical and clinical images. To
address the impact of image resolution (vis-vis voxel size) on radio-
mic features, we extracted quantitative image features across three
resolutions. In addition, we correlate the dependency of radiomics
features on tumour volume to identify volume-independent radiomic
features. The workflow is performed in the context of a triple nega-
tive breast cancer (TNBC) co-clinical trial with the primary objective
of identifying robust T1w and T2w radiomic features for both preclin-
ical and clinical imaging pipelines. We demonstrate that tumour vol-
ume, image noise, and image resolution significantly impact radiomic
features, suggesting that these factors are a major consideration in
designing co-clinical trials with radiomic endpoints.
2. Methods
2.1. Overview of harmonization and analytic scheme
The analytic pipeline to characterize the sensitivity of image fea-
tures is displayed in Fig. 1a. The co-clinical raw images were proc-
essed to annotate regions of interest (ROI), such as tumour and
muscle regions slice by slice to build 3D ROIs. Histogram and texture
features were extracted and analysed to investigate the effects of
noise on co-clinical MR image radiomic features. The noise level was
estimated from low noise (SNR>25) “baseline” images. The sensitiv-
ity to image resolution was investigated through multiple acquisi-
tions of the same PDX during the same imaging session. Using the
same data, the dependency of radiomic features on tumour volume
was established.
2.2. TNBC PDX model and growth characterization
Gene expression analyses of 93 TNBC patients samples (29657
unique genes/probes) was performed to identify six TNBC subtypes
including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a
mesenchymal (M), a mesenchymal stemlike (MSL), and a luminal
androgen receptor (LAR) subtype as described previously [21,22]. IM,
M, BL1, and BL2 TNBC PDX sub-types served as a preclinical platform
to assess the sensitivity of radiomics features. Tumours were
implanted in the 4th mammary fat pad of NSG mice. Mice were exam-
ined regularly for palpable tumours. Tumour volumes were calcu-
lated from calliper measurement using the formula 1/6*p*L*W2 with
the goal of recruiting PDX with tumour volumes of ~250mm3. The
variability in timing and rate of tumour growth both between and
within PDX proved somewhat challenging in maintaining consistent
recruitment schedule, and resulted in wide range of tumour volumes
(See Fig. 1b). Details regarding animals, surgeries, and tumour xeno-
grafts were reported previously [22,23]. All animal experiments were
conducted in compliance with the Guidelines for the Care and Use of
Research Animals established by Washington University’s Animal
Studies Committee.
2.3. MR image acquisition
Clinical MR Imaging. The study protocol was approved by the insti-
tutional review board and written informed consents were obtained
from all prospective patients. Twenty-five stage II or III TNBC patients
were recruited into an ongoing co-clinical imaging trial (ClinicalTrial.
gov ID # NCT02124902). Clinical MR imaging protocol was imple-
mented on the Siemens mMR Simultaneous PET/MR. The MR proto-
col included: T1W (2D TSE multi slice, turbo factor 3, echo time (TE)
11 ms, repetition time (TR) FOV 320 £ 320, spatial resolution
1.0mm £ 1.0mm X 3.0mm), and T2W (2D TSE multi slice with an
inversion pulse, TI=170 ms, turbo factor 11, TE = 58 ms, TR= 7040 ms,
FOV 448 X448, spatial resolution 0.759mm X 0.759mm X 3.0mm).
Research in context
Evidence before this study: Magnetic resonance imaging (MRI)
radiomic analyses pipelines are widely implemented to predict
and assess response to therapy as well as aid in stratification of
patients. Numerous studies previously characterized the test-
retest performance of radiomic features through phantom stud-
ies and clinical imaging studies.
Added value of this study: Beyond test-retest performance, a
critical consideration in implementation of radiomic pipelines
is site-to-site variability in image acquisition protocols such as
image resolution and image characteristics such as signal-to-
noise. This is especially applicable to preclinical imaging proto-
cols where unlike clinical imaging, there are no established
guidelines for best practices and there is significant variability
in image acquisition parameters. In addition, a critical consider-
ation in implementation of radiomic analysis is the sensitivity
of radiomic features to target tissue volume. This study investi-
gates the sensitivity of radiomic features to noise, resolution,
and tumour volume, with emphasis on co-clinical (preclinical
and clinical) harmonization of radiomic features to support
translational therapeutic studies with imaging as an endpoint.
Implications of all the available evidence: Our evidence indi-
cates that tumour volume, noise, and image resolution signifi-
cantly impact radiomic features in co-clinical imaging. We
propose a volume-dependency correction scheme and identify
a set of robust radiomic features for co-clinical imaging studies.
This work highlights the need to harmonize preclinical and
clinical image acquisition protocols and radiomic analyses pipe-
lines to enable multi-site translational studies with radiomic
analysis as an endpoint.
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Preclinical MR Imaging. TNBC PDX displayed highly variable
growth patterns both within and between PDX. Calliper-based
measurements of tumour volumes, which are known to overesti-
mate tumour volumes, are depicted in Fig. 1b. Corresponding MR-
based tumour volumes were in the range of 100  650 mm3. MR
imaging was performed on the MR Solutions simultaneous 7T MR/
PET scanner (MR Solutions, Guildford, UK). The multi-parametric
(MP) MR protocol included: T1W (2D FSE multi slice, echo train
length 4, echo spacing 11 ms, effective TE =11 ms, respiratory
gated with effective TR = 1s, respiration rate kept around
60 breaths/min, spatial resolution 0.25mmX0.25mmX1.0mm), and
T2W (2D FSE multi slice, echo train length 7, echo spacing 15 ms,
effective TE = 45 ms, respiratory gated with TR = 5 s, respiration
kept around 60 breaths/min. PDX mice were anesthetized with 1-
2% isoflurane throughout imaging sessions. Given the lag (upwards
of 6 months) in developing PDX, three cohorts of PDX were used
for different experiments:
1) Preclinical imaging to assess sensitivity to resolution. Six PDX
were imaged at three different in plane resolutions
0.125mm £ 0.125mm £ 1mm, 0.25mm £ 0.25mm £ 1mm, and
0.5mm £ 0.5mm £ 1mm, referred to henceforth as high,
medium, and low resolution, respectively, while keeping same
FOV (Fig. 2).
2) Preclinical imaging to assess sensitivity to noise: Additional PDX
mice were used to investigate the sensitivity to noise—5 at
high resolution and 19 at medium resolution per above reso-
lution.
3) Preclinical imaging to assess dependency of radiomic features on
tumour volume. The dependency of radiomic features on tumour
volume was characterized using 31 image datasets from 12 PDX
at different time points volumes for a total of 31 datasets. Theses
scans were acquired on an Agilent 4.7T scanner with in-plane
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Fig. 1. (a) Overview of analytic methods. Patient-derived tumour xenografts (PDX) were generated from human tumour biopsies from TNBC patients. Human imaging was per-
formed on the Siemens mMR PET/MR scanner. PDX were imaged on Agilent 4.7T or MR Solutions 7T MR scanner. Radiomics analysis, including histogram (1st order), grey level co-
occurrence matrix (GLCM) or second order and higher order features, was performed on 2D and 3D segmented tumours to assess volume dependency, sensitivity to noise, and sen-
sitivity of resolution. (b). Growth profile of TNBC PDX used in this study based on calliper measurements.










Fig. 2. Single slice for each of three different resolutions. PDX were imaged at three different in plane resolutions 0.125mm£0.125mm£1mm, 0.25mm£0.25mm£1mm, and
0.5mm£0.5mm£1mm, referred to henceforth as high, medium, and low resolution, receptively, while keeping a constant FOV. High resolution left; medium resolution, middle;
high resolution, right. Top row depicts T1w images, while bottom row depicts T2w MR images.
Table 1A
Co-clinical T1w and T2w image descriptors for sensitivity to noise and resolution.
MR Seq. Metric SNR (in dB) Estimated
noise level







Number of voxels in
largest cross section
area
Clinical* T1w (N=25) Range 18.9 45.4 0.20  0.68 1,182  43,309 268  2,837 366  4,600 93  1,394
Avg§SD 30.6 § 07.6 0.37 § 0.13 6,773 § 8155 1,259 § 760 1,229 § 834 305 § 254
Median 29.6 0.37 4725 984 1129 244
95% CL 03.2 0.05 3366 321 344 105
T2w (N=25) Range 21.3 74.0 0.25  0.93 1,873  4,4691 832  23,513 518  4,567 230  2,403
Avg§SD 35.7 § 11.7 0.57 § 0.13 7,603 § 8360 3,592 § 4,424 1,387 § 820 643 § 435
Median 33.1 0.57 5305 2244 1226 527
95% CL 4.9 0.05 3451 1826 339 179
Preclinical**
High Res T1w (N=11) Range 17.0 64.4 0.69  2.56 174  467 11,362  29,896 33  83 2,157  5,287
Avg§SD 33.1 §12.7 1.38 § 0.57 317 § 109 20,525 § 7142 49 § 15 3,184 § 970
Median 33.1 1.18 350 22885 42.4 2771
95% CL 8.5 0.38 73 4798 10 652
T2w (N=11) Range 19.4 65.4 0.98  2.46 174  456 11,362  29,201 33  80 2,157  5,119
Avg§SD 33.8 § 13.3 1.5 § 0.43 309 § 114 20,037 § 7,483 48 § 15 3,138 § 978
Median 33.0 1.35 350 22885 42 2771
95% CL 8.1 0.29 77 5027 10 657
Med Res T1w (N=25) Range 17.3 63.7 0.45  1.95 75  438 1,447  7,175 20  61 372  992
Avg§SD 33.5§ 11.6 0.96 § 0.33 245 § 123 4,157 § 1901 38 § 13 651 § 189
Median 30.9 0.96 198 3357 35 621
95% CL 4.8 0.13 51 785 5 78
T2w (N=25) Range 18.0 52.2 0.51  1.59 64  436 1,234  7,141 17  61 320  992
Avg§SD 32.78§ 7.8 0.97 § 0.22 241 § 125 4,091 § 1,931 37 § 13 639 § 189
Median 30.9 0.94 190 3518 34 591
95% CL 3.3 0.09 51 797 5 78
Low Res T1w (N=6) Range 20.7 65.5 0.47  1.69 172  442 706  1,809 37  72 150  294
Avg§SD 36.6§ 16.7 0.79 § 0.46 357 § 96 1,464 § 3393 55 § 13 225 § 54
Median 31.7 0.66 386 1583 59 243
95% CL 17.6 0.48 101 412 14 57
T2w (N=6) Range 19.663.9 0.36  1.21 172  442 706  1,809 37  72 150  294
Avg§SD 35.2§ 15.5 0.73 § 0.29 358 § 97 1,467 § 395 55 § 13 226 § 54
Median 32.2 0.70 386 1583 60 246
95% CL 16.3 0.31 101 415 14 57
* Clinical image voxel size (x,y,z): T1 (1.0mm, 1.0mm, 3mm); T2w (0.76mm, 0.76mm, 3mm).
** Preclinical image voxel size (x,y,z): High Res T1w and T2w (0.125mm, 0.125mm, 1mm); Med Res T1w and T2w (0.25mm, 0.25mm, 1mm);
Low Res T1w and T2w (0.5mm, 0.5mm, 1mm).
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Table 1A tabulates descriptive data for clinical and preclinical
studies to asses sensitivity to noise and resolution, whereas Fig. 1b
tabulates the PDX descriptive data to assess dependency of radiomic
features on tumour volume.
2.4. Image segmentation
Digital Imaging and Communications in Medicine (DICOM) and
Flexible Data Format (FDF) MRI data were transferred into MATLAB
(2019a) prior to texture analysis and successive analysys were exe-
cuted in MATLAB. T1w and T2w MR images were analysed separately
with ROIs drawn manually on every slice. Tumour volumes were cal-
culated by determining the number of voxels in the volume of inter-
est multiplied by the voxel dimension (mm3) for each MR sequence.
In segmenting tumours at the three resolutions, ROIs were defined
on high-resolution images and were applied to lower resolution
images as to not bias results potentially due to ROI variability.
2.5. Extraction of radiomic features
Radiomic features were extracted per ISBI guidelines [25]
using formulations from previously published work [26,27].
Forty-eight radiomics features were extracted from 2D (single
slice with largest cross section) and 3D (whole tumour) seg-
mented tumours and muscle as normal tissue ROIs. Single slice
was chosen based on the largest cross section area of the tumour.
MR image data were transferred into image matrix in MATLAB
and features were extracted from segmented 3D/2D matrix. MAT-
LAB R2019a was used for the radiomic feature extraction and
analysis. Equal-probability quantization algorithms to quantize
raw data into grey level (Ng) was implemented using histeq
MATLAB functions. MR data normalization suggested by Collewet
[28] was implemented. Resampling to isotropic voxel size was
applied to reduce the effect of resolutions for GLCM, GLRLM,
GLSZM and NGTDM matrix generation. Supplement Table S1 sum-
marizes the features used within. The features are broadly catego-
rized as: first order features extracted from intensity histogram,
second order statistics, and higher-order features. First order
global features were extracted directly from intensity histogram
of raw data. Mean, variance, standard deviation, skewness, and
kurtosis were extracted from first order statistics. Sixty-four fixed
bin number grey level quantization was used for histogram analy-
sis of variance, skewness, and kurtosis of first order global fea-
tures [26]. Co-occurrence matrix (GLCM) features Energy,
Contrast, Correlation, Homogeneity, Variance, Sum Average, and
Entropy were computed with fixed bin number grey level quanti-
zation number 64. Lastly, thirty-one higher-order textures
[26,2931] were extracted from Grey-level run-length matrix
(GLRLM), Grey-level size zone matrix (GLSZM) and Neighborhood
grey-tone difference matrix (NGTDM) with fixed number grey
level quantization number 64. GLCM, GLRLM, GLSZM and NGTDM
were generated from 3D ROI with 26 voxels connectivity (8 con-
nectivity in 2D).
2.6. Evaluation of volume-independent radiomic features
Radiomic features were extracted from 31 T2-weighted preclini-
cal MR images. Voxel intensities within a region of interest (ROI)
were resampled into a limited number of discrete values or bin sizes
before calculating feature values. Radiomic features were extracted
as described above. The magnitude of radiomic features was
regressed against their corresponding tumour volume using linear
and non-linear models: linear, power, log, exponential or 2nd order
polynomial (see Statistical method below). In an attempt to correct
for volume dependencies, the volume-dependent features were nor-
malized by volume for subsequent analysis. Features that had a sig-
nificant linear correlation with volume, were normalized by dividing
by tumour volume; otherwise, if inversely proportional to tumour
volume, features were normalized by multiplying by tumour volume.
Nonlinear correlated radiomic features were normalized by as per
the fitted model.
2.7. Evaluation of noise effects on radiomics features
Addition of External Noise. To examine the sensitivity of the
selected radiomics features to SNR, the baseline images were normal-
ized to 0-255 and then degraded by the addition of six different levels
of Gaussian noise. We considered Gaussian noise in this study as
Rician distributions are nearly Gaussian for SNR>2 as described pre-
viously [32]. Gaussian noise with zero mean and standard deviation
(s) proportional to s=a£255 where a denotes the noise magnitude
constant (i.e., G (0, a£ 255)) was added to images. Six different levels
of a (0.001, 0.005, 0.010, 0.015, 0.025, and 0.05) were added resulting
in SNR range of 45 dB to 6 dB corresponding with si=(0.255, 1.27,
2.55, 3.825, 6.735, 12.75).
Noise level estimation (C). A patch based method from single noisy
2D image was used to estimate noise levels [33]. The images first nor-
malized to 0-255 intensity scale to remove intensity dependencies.
The noise level estimated (C) of 3D image was calculated by taking
average of noise from all multi-slice images. The minimum variance
was calculated using principal component analysis (PCA) from the
covariance matrix. Images were decomposed into patch sizes of 3£3,
5£5, and 7£7 depending on the test image dimension. The minimum
eigenvalue of the covariance (<0.5) matrix was considered as weak
texture patches. Therefore, the noise was easily measured from the
selection of weakly textured patches. The richer textures were larger
maximum eigenvalues. Thus, the quantitative level of the texture
strength of the image patches were measures from eigenvalue of the
gradient covariance matrix. Then weak patches (Wp) were selected
from the gradient covariance matrix with the maximum eigenvalue
less than some threshold (Th). The threshold was calculated from the
inverse gamma cumulative distribution function where the signifi-
cance level can also be changed manually. In practice, low signifi-
cance levels indicate enhanced sensitivity to noise. An iterative
framework was used to ensure the convergence of noise level sn.
Manual iteration reduces the computational time compared to auto-
matic iteration until convergence.
The signal to noise ratio (SNR) and root mean square error (RMSE)
[34] were also implemented to quantify noise level of original and
noisy image. SNR is represented by the ratio of the average signal
intensity of tumour region over the standard deviation of the noise,
given in decibel (dB). The RMSE between two images I(x,y) and I*
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where, I(x,y) is image before noise added and I*(x,y) is the image after
noise added externally.
Table 1B
Co-clinical image descriptive data for volume dependent radiomic features.
3D Tumour Volume (mm3) 3D tumour number of voxels
Range (N=31) 63.82-418.70 1673-10,976
Avg § SD 177.1§83.2 4,641.6§ 2,180.3
Median 172.8 4,530.5
95% CL 31.1 814.2
*Image voxel size (x,y,z) :0.195 £ 0.195 £ 1 mm3.
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2.8. Statistical analysis
Volume-dependent radiomic features: The Pearson correlation
coefficient was determined to assess the correlation between radio-
mic feature and the tumour volume. Correlations with P-value < 0.05
were considered significant (Table 2). We did not perform multiple
hypothesis testing as to not undercount the number of potential sig-
nificant correlations. Linear or nonlinear least squares regression was
used to fit all significant volume-dependent radiomic features.
The Akaike Information Criterion (AIC) and Bayesian Information
Criterion (BIC) were calculated for each model, and the appropri-
ate model was selected based on the minimum value of AIC and
BIC. STATA 12 (StataCorp, College Station, TX) was used for
regression and statistics.
Sensitivity of resolution on radiomic features: Radiomic fea-
tures were extracted from low, medium, and high-resolution
images (as described above). The ratio of the radiomic feature
extracted from low (L:H) and medium (M:H) resolution images
was normalized to those from the corresponding high resolution
image for each PDX tumour. A ratio of unity denotes agreement
between the different resolutions tested. Subsequently, the aver-
ages, mL: H and mM: H and corresponding SDs and coefficient of
variation (CV = SD/m) were determined for the set of L:H and M:
H ratios for each feature. The magnitude of the sensitivity is
defined by the bias from unity, i.e., bL:H=1- mL: H and bM:H=1- mM:
H. Tables S2 and S3 tabulates the statistics for the ratios for each
radiomic feature.
Cross-correlation between radiomic features and identifica-
tion of independent signatures: The cross-correlation between the
48 features was calculated using Pearson correlation. A P-value<0.05
was considered significant (Supplemental Table S4). Additionally,
principle component analyses (PCA) was performed on the 48 fea-
tures on the volume data.
Relative percent change (RPC) and average percentage
changes (APC) noise sensitivity: Relative change in image feature
was calculated from the ratio between the change in image feature
(before addition of noise and following addition of noise) relative
to baseline (before addition of noise). Relative percentage change
(RPC) is the relative change calculated as a percentage. The aver-
age percent change (APC) was calculated by taking average of
RPCs.
2.9. Role of the funding source
Funders had no role in the study design, data collection, data anal-
ysis, interpretation, and writing of the manuscript.
3. Results
Table 1A tabulates the range of estimated noise (C), tumour vol-
umes, and corresponding number of voxels (2D and 3D) in the co-
clinical study. Since image features are dependent on the information
density embedded in the image (and hence, the number of voxels
defining an image) a consideration of resolution-to-scale is needed
when harmonizing preclinical and clinical image acquisition pipe-
lines. For the range of tumour volumes in the clinical study, the corre-
sponding number of voxels defining a T1w and T2w imaged was on
average 1,259§744 and 3,592§4,335, respectively. Of the three pre-
clinical image resolutions tested, the medium resolution image acqui-
sition protocol yielded comparable statistics to the clinical images in
terms of estimated noise and number of voxels defining a single
tumour slice (2D slice) or whole segmented tumour (3D). Table 1B
Table 2
Volume-dependent radiomic texture features.
Features name P-Value Stats Linear Exponential Log Power Polynomial
GLCM.Contrast 0.71£10-3 AIC 261.3 261.1 259.6 260.0 262.2
BIC 276.1 275.9 274.4 274.8 281.9
GLCM.Correlation 0.37£10-3 AIC -144.3 -141.9 -147.3 -146.5 -144.6
BIC -129.5 -127.1 -132.5 -131.7 -124.8
GLRLM.SRE 0.31£10-9 AIC -19.6 -6.2 -9.9 -19.0 -18.1
BIC -4.8 8.6 4.9 -4.2 1.6
GLRLM.RLN 0.73£10-6 AIC -297.6 -297.2 -297.4 -298.7 -287.3
BIC -282.8 -282.4 -282.6 -282.9 -267.6
GLRLM.RP 0.32£10-6 AIC -337.5 -338.4 -334.3 -340.0 -338.2
BIC -322.7 -323.6 -319.5 -325.2 -318.4
GLSZM.SZE 0.34£10-3 AIC -251.4 -257.6 -256.8 -257.1 -250.4
BIC -236.6 -242.8 -242.0 -242.3 -230.7
GLSZM.LZE 0.22£10-13 AIC -48.3 -2.2 -38.9 -47.3 -47.1
BIC -33.5 12.6 -24.1 -32.5 -27.4
GLSZM.ZSN 0.32£10-3 AIC -206.2 -208.8 -215.6 -216.4 -211.3
BIC -191.4 -194.0 -200.8 -201.6 -191.6
GLSZM.ZP 0.74£10-6 AIC -202.6 -203.0 -204.1 -203.7 -205.9
BIC -187.8 -188.2 -189.3 -188.9 -192.2
GLSZM.LZLGE 0.12£10-3 AIC -85.1 -84.8 -80.3 -79.9 -84.7
BIC -71.0 -70.3 -65.5 -65.1 -65.0
GLSZM.LZHGE 0.68£10-9 AIC 482.9 493.7 492.7 483.8 484.1
BIC 497.7 508.5 507.5 498.6 503.8
GLSZM.GLV 0.14£10-5 AIC -381.5 -387.7 -375.8 -389.7 -383.1
BIC -366.7 -372.9 -361.0 -376.0 -363.4
GLSZM.ZSV 0.81£10-7 AIC -773.9 -834.2 -809.9 -837.2 -791.3
BIC -759.1 -819.4 -795.1 -822.4 -771.6
NGTDM.Coarseness 0.99£10-10 AIC -490.9 -500.6 -380.5 -533.8 -495.2
BIC -476.1 -485.8 -365.7 -519.0 -475.5
NGTDM.Busyness 0.28£10-10 AIC -126.3 -115.5 -107.4 -120.2 -124.1
BIC -121.5 -120.7 -92.6 -105.4 -114.4
NGTDM.Strength 0.52£10-8 AIC -31.4 -44.7 -49.8 -50.0 -46.8
BIC -16.6 -29.9 -35.0 -35.2 -27.1
*Minimum values of AIC and BIC were highlighted with bold
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summarizes descriptive data for correlation of volume to radiomic
features.
3.1. Volume-dependent radiomics features
In all, 16 T2w 3D radiomic features were found to be volume
dependent as tabulated in Table 2 along with P-values indicating the
significance of the correlation to volume (assuming a linear model)
and AIC and BIC scores for the considered models. Tumour volume
has greater influence on higher order features extracted from GLSZM
(8 of 16 features). In addition, tumour volume influenced select fea-
tures derived from GLCM, GLRLM and NGDTM. The voxels adjacent to
a given position with same grey value may have an indirect influence
on volume-dependent features. To remove the dependency on vol-
ume, we attempted to normalize the volume-dependent features as
described in Methods section. Following correction, volume-depen-
dent features were no longer volume-dependent. Pre- and post- vol-
ume dependency correction regression plots is depicted in Fig. 3.
3.2. Cross-correlation of radiomic features and dimension reduction of
radiomic signature
We additionally evaluated the cross-correlation of the radiomic
features with the goal of identifying a panel of radiomic signatures
which may be independent of tumour volume. The cross-correlation
of radiomic features is depicted in heatmap of Fig. 4a. The number of
within-group correlations is high in both GLCM (50%) and NGTDM
(40%) groups, while the 1st order features (17.9%), the GLRLM (17.9%)
and SLSZM (20%) groups have fewer within group correlations. In
general, we observe that 1st order features are mildly correlated to
higher order features and higher order features are highly correlated
to each other. The application of PCA to derive a panel of independent
radiomic signatures is depicted in the radar plot of Fig. 4b. The radar
plot depicts the loading of each feature from top four principal com-
ponents. To further delineate volume dependency, we tested the cor-
relation between PCA-derived radiomic features (with loading
greater to 0.1) to volume (Fig. 4c). The correlation remained signifi-
cant suggesting that dimension reduction does not correct volume
dependency.
3.3. Sensitivity of radiomic features to noise
Representative co-clinical T1w and T2w MR images are displayed
in Fig. 5 after adding varying magnitudes of Gaussian noise. The per-
formance of the noise estimation algorithm was compared to RMSE
and SNR. The correlation between externally added noise vs. noise
measured, and the corresponding SNR and RMSE with noise mea-
sured is depicted in Fig. 6. Fig. 6a suggests a linear correlation
(R20.99) between added noise and estimated noise. In the absence
of added noise, there are differences in the levels of noise measured
between preclinical and clinical images. Fig. 6b and Fig. 6c depict the
correlation between estimated noise and RMSE and SNR, respec-
tively. With no noise added, estimated noise is greater than zero (and
RMSE is zero) due to inherent noise in the baseline (prior to the addi-
tion of noise) image. RMSE increases linearly (R20.99) with added
Gaussian noise. There is a divergence in preclinical and clinical corre-
lation between RMSE and noise measured starting atC =3. The linear
relationship (R20.99) between noise estimation and RMSE (Fig. 6b)
and exponential (R20.95) decrease of SNR with the increase of noise
(Fig. 6c) highlights the robustness of the texture-based noise estima-
tion method. This texture-based method can be used to estimate
noise on an image-by-image basis and thus define customized retro-
spective assessment of the diagnostic study in co-clinical study
design.
Fig. 7a displays sensitivity of radiomics features to noise (via APCs)
at varying noise magnitudes. Four major cases are depicted: features
extracted from single 2D slice and whole-tumour (3D) tumour of
T1w and Tw2 images with addition of Gaussian noise. Features vary-
ing less than 10% (approx. SNR of 26 in T1w and 28 in T2w images)
were considered as less sensitive to noise in co-clinical images. Of the
48 features examined, 38 features exhibited APC < 10% for preclinical



































































































Fig. 3. Volume-dependent radiomic features. Regression plots of 48 T2w 3D radiomic features as function of volume for sixteen volume-dependent features that were converted
to volume independent. The radiomic feature is depicted before and after normalization marked with Pre and Post in subplots. The corresponding P-value and R2 values are dis-
played in the corresponding subplots. P-values indicate significance of linear correlation.
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noise C  1.5 (corresponding to SNR  28); 37 features exhibited
variability APC<10% for clinical T1w with estimated noise C  0.9
(corresponding to SNR  30); and 42 features were variability < 10%
for clinical T2w on estimated noise C  1.5. Mean feature exhibited
<10% variability across all realistic noise levels for T1w and T2w. In
all, thirty-one features in preclinical and clinical image features
exhibited APC<10% for each T1w and T2w. Fig.s 7b (2D tumour) and
7c (3D tumour) highlight the proportion of radiomic features at a
given bias for a given noise level. Overall, T2w radiomic features are
more robust to noise than T1w, with 3D analyses being more robust
than 2D analyses.
3.4. Sensitivity of radiomic features to resolution
Figs. 8 and 9 depict the sensitivity of T1w and T2w radiomic
features to resolution, respectively. The ratio of low and medium to
high (L:M and M:H, respectively) image features was used to assess
the sensitivity of radiomic features to resolution. The mean and stan-
dard deviations of ratios are calculated for each feature while the
coefficient of variation (CV) is provided as supplement table
(Supplemental Table S2 and Table S3). To ascertain the sensitivity of
the features, we determined the fold-bias of the ratio from unity.
Generally, the number of significant features different from unity
was higher in L:H compared to M:H. In addition, 2D radiomic features
exhibited higher prevalence of bias compared to 3D image features.
Many first order and GLSZM features were more sensitive to resolu-
tion than other higher order features, and generally, single slice (2D
tumour) radiomics features were more sensitive to resolution than
3D based image features. The variability of the average fold-bias, as
provided by the CV, is also a critical consideration for each feature.
While several of the features did not exhibit significant bias (i.e.,
were not found to be significantly different from unity), they exhib-
ited high CV as depicted in Figs. 8,9 and summarized in
Supplemental Table S2 and Table S3. Thus, there is an added con-
straint in minimizing both the bias and the CV. Given the impact of
reduced resolution on feature metrics, we tested whether isotropic
up-sampling of resolution from low and medium to high resolution
would alleviate the bias in resolution. As summarized in
Supplemental Table S5, there is significant bias in image features fol-
lowing up-sampling, suggesting that up-sampling cannot correct for
resolution bias in image features.
4. Discussion
Radiomic analysis has been proposed as a step towards realization
of precision medicine by providing means to interrogate the spatial
complexity of tumours in vivo [11,35]. A recent publication by the
Imaging Biomarker Standardization Initiative (ISBI) identified 174
Fig. 4. Identification of independent radiomic signatures. (a) Pearson (r) cross-correlation between 48 T2w 3D radiomic feature. (b) Radar plot following PCA to identify inde-
pendent radiomic signatures (RadSig). (c) Correlation between independent PCA-derived radiomic signature to volume. P-value indicate significance of linear regression.
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Fig. 5. The output after added varying magnitude of (a2, a4, and a6) Gaussian noise on input co-clinical T1w and T2w breast MR image is shown in (a) and (b). SNR corresponding to















































Fig. 6. Plot of noise added of magnitude (a) into 3D MR vs noise estimated from 3D MR co-clinical image. (a) Noise added of magnitude (a) vs noise estimated using texture-based
method; (b) noise estimated vs RMSE measured after added noise; (c) noise estimated vs SNR measured after added noise.
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radiomic features to that end [25]. The radiomic features presented
within are only a subset of features available to define phenotypes of
an image as not all features are applicable for co-clinical imaging tri-
als. Numerous studies previously characterized the robustness and
test-retest performance of radiomic features [36,37] through phan-
tom studies and clinical imaging studies. Beyond robustness of fea-
tures, a consideration in implementation of radiomic pipelines is
site-to-site variability in image acquisition parameters such as image
resolution and image characteristics such as signal-to-noise. In addi-
tion, a critical consideration in implementation of radiomic analysis
in oncologic imaging is the sensitivity of radiomic features to tumour
volume. This is particularly relevant in longitudinal studies during
which tumour volumes will change with the course of the disease or
following therapy.
Our results indicate that numerous radiomic features are depen-
dent on tumour volume suggesting that a normalization scheme is
needed to account for the influence of tumour volume on radiomic
features. Of the radiomic features tested, 16 were found to be volume
dependent. We subsequently attempted to correct for volume depen-
dencies using both linear and non-linear models and were successful
in removing all volume dependencies based on statistical consider-
ation, although for select features correlations remain. We also per-
formed PCA in an effort to identify a radiomic signature that is
volume independent. However, the panel of radiomic features fol-
lowing dimension reduction still correlated to volume, suggesting
that dependency on volume is a major consideration in designing
imaging studies with radiomic analysis as an endpoint. Importantly,
the utility of the volume-dependency correction schemes will need
to be tested in the context of therapeutic studies. Of consideration, in
MR imaging there are trade-offs in acquisition time, voxel size (reso-
lution), and signal-to-noise (SNR). Cattell et al. and Baessler et al. per-
formed phantom studies to characterize the robustness of select
radiomic features [36,37]. Recently, Shafiq-Ul-Hassan et al [38] char-
acterized the dependencies of clinical computed-tomography (CT)
radiomic features on voxel size. Sensitivity of radiomic features due
to motion and noise in CT were also investigated using both simu-
lated and clinical data [39]. Bagher-Ebadian et al., characterized the
impact of smoothing and noise on robustness of CT radiomic features
in context of head and neck cancer [40]. The sensitivity of image
reconstruction in positron emission tomography (PET) has also been
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Fig. 7. Sensitivity of radiomic features to noise. (a) Average percent change (APC) of radiomic features as a function of noise. The X- axis corresponds to added noise level [a1  33
(SNR); a2 32(SNR); a3 28(SNR); a4 23(SNR); a5 17(SNR); a6 11(SNR)], and Y-axis corresponds to the radiomic features (1- 48)(see Supplemental table S#) . (b) and (c) depict
the proportion of radiomic features at different bias with increasing noise for 2D and 3D analyses, respectively. The bias is denoted by the colour-scale legend below panel C.
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Fig. 8. Sensitivity of T1w radiomics features to resolution. Ratio of low-to-high (L:H) and medium-to-high (M:H) radiomic features using either (a) a single slice (2D) or (b) the
whole tumour (3D) for the analysis. Line at unity indicates perfect agreement between lower resolution and high-resolution images. *denotes radiomic features whose mean ratio
is significantly different from unity using a Student’s t-test; #denotes radiomic features with CV > 20%.
Fig. 9. Sensitivity of T2w radiomics features to resolution. Ratio of low-to-high (L:H) and medium-to-high (M:H) radiomic features using either (a) a single slice (2D) or (b) the
whole (3D) tumour for the analysis. Line at unity indicates perfect agreement between lower resolution and high-resolution images. *denotes radiomic features whose mean ratio
is significantly different from unity using a Student’s t-test; #denotes radiomic features with CV > 20%.
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Table 3
Summary of robust radiomic features.
Dark grey shading indicates robust feature. Light green shading indicates corrected volume dependency; Light blue shading indicates bias variability in resolution with
CV>20%
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extensively investigated using both physical phantoms and patient
data [41]. To our knowledge, however, no study has investigated the
sensitivity of radiomic pipelines in the context of co-clinical MR
imaging trials (preclinical and clinical).
As it relates to sensitivity of features to noise, our data suggests
that performance of radiomic features can be improved significantly
if SNR > 28 in particular for rich texture images. In an effort to har-
monize preclinical and clinical noise levels or SNR, we developed an
unbiased algorithm to harmonize noise levels and identified 31 com-
mon co-clinical radiomic features exhibiting less than 10% variability
in the presence of noise ranging from SNR 28 to 33. Overall, features
extracted directly from histogram were less sensitive to noise com-
pared to second order and higher order features except skewness
and kurtosis. In addition, image features derived from T1w images
tended to be more susceptible to noise than T2w images. In general,
features extracted from 3D exhibited less sensitivity than features
extracted from 2D in both clinical and preclinical images. The impli-
cations of the latter are significant since some radiomic analysis pipe-
lines use 2D images to characterize the heterogeneity of images, and
interslice differences may produce bias in radiomic analysis. Impor-
tantly, if using 2D slices for radiomic analysis, interslice variability
may further bias radiomic analysis in particular in longitudinal stud-
ies. Finally, the sensitivity of radiomic features to resolution cannot
be overstated. Clinical image acquisition pipelines are well standard-
ized within an institution and between institutions, partly since they
cater to patient standard of care, but also owing to numerous initia-
tives such the quantitative imaging network (QIN) and the quantita-
tive imaging biomarker alliance (QIBA). In contrast to clinical
imaging, preclinical imaging acquisition pipelines are not well opti-
mized nor standardized between institutions, and in some cases even
within an institution highlighting the need for robust radiomic fea-
tures to support co-clinical imaging trials.
As a way of summary, Table 3 tabulates robust radiomics fea-
tures characterized in this study. A feature was considered robust
if it displayed less than 10% bias in noise and resolution, in 2D and
3D analyses schemes, or is volume independent. A challenge in all
radiomic analyses schemes is the lack of reproducibility within
and between institutions, as published studies have been difficult
to reproduce and validate [4245]. This has been partly attributed
to differences in software implementations of radiomics features
and the image processing schemes required to compute features
[42,44,46,47]. Another source of variability, as highlighted within,
is differences in image acquisition. Ideally, in designing co-clinical
imaging studies, a feature should be selected that’s robust in both
preclinical and clinical image acquisition protocols. The implica-
tions of the work further highlight the need for consistency in
imaging acquisition protocols, both within a single site, as well as
in multi-site studies to enable integration of data across sites.
Importantly, our data highlight the need to develop best practices
in preclinical imaging to enable the translation imaging studies in
support of precision medicine.
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